Verona Pharma PLC Notice of Results (6404X)

TIDMVRP

RNS Number : 6404X

Verona Pharma PLC

23 February 2017

Verona Pharma plc

Notice of Results

23 February 2017, London - Verona Pharma plc (AIM: VRP) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, expects to announce its preliminary results for the year ended 31 December 2016 on Monday 27 February 2017.

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti--inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the timing of our announcement of preliminary results for the year ended 31 December 2016.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

-Ends-

For further information please contact:

 
 Verona Pharma plc                                Tel: [phone] 
                                                                 4200 
 Jan-Anders Karlsson, Chief                     [e-mail] 
  Executive Officer 
 
 N+1 Singer (Nominated Adviser                    Tel: [phone] 
  and UK Broker)                                                 3000 
 Aubrey Powell / James White 
 
 FTI Consulting (UK Media and                     Tel: [phone] 
  Investor Enquiries)                                            1000 
 Simon Conway / Stephanie Cuthbert     [e-mail] 
  / 
  Natalie Garland-Collins 
 
 ICR, Inc. (US Media and Investor 
  Enquiries) 
 James Heins                                     Tel: [phone] 
                                               [e-mail] 
 Stephanie Carrington                            Tel. [phone] 
                                      [e-mail] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLIFVRFRIVFID

(END) Dow Jones Newswires

February 23, 2017 02:02 ET (07:02 GMT)